Pimecrolimus cream 1% in the treatment of lichen sclerosus

Gynecologic and Obstetric Investigation

Volumn 63, Issue 3, 2007, Pages 151-154

  Nissi, Ritva ^a   Eriksen, Heidi ^b   Risteli, Juha ^b   Niemimaa, Marko ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF OULU   (Finland)

Author keywords

Immunomodulation; Lichen sclerosus; Pimecrolimus

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; CORTICOSTEROID; PIMECROLIMUS;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLLAGEN SYNTHESIS; CREAM; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LICHEN SCLEROSUS ET ATROPHICUS; MULTICENTER STUDY; PRIORITY JOURNAL; PRURITUS; SEXUAL DYSFUNCTION; SKIN ATROPHY; SKIN MANIFESTATION; TREATMENT OUTCOME;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DERMATOLOGIC AGENTS; FEMALE; HUMANS; LICHEN SCLEROSUS ET ATROPHICUS; MIDDLE AGED; OINTMENTS; PILOT PROJECTS; REMISSION INDUCTION; SAFETY; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34047174143     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096736     Document Type: Article

References (21)

1. Powell JJ, Wojnarowska F: Lichen sclerosus. Lancet 1999;353:1777-1783.
2. Tasker GL, Wojnarowska F: Lichen sclerosus. Clin Exp Dermatol 2003;28:128-133.
3. Neill SM, Tatnall FM, Cox NH: Guidelines for the management of lichen sclerosus. Br J Dermatol 2002;147:640-649.
4. Dalziel KL, Millard PR, Wojnarowska F: The treatment of vulvar lichen sclerosus with a very potent topical steroid (clobetasol propionate 0.05%) cream. Br J Dermatol 1991;124:461-464.
5. Dalziel KL, Wojnarowska F: Long-term control of vulval lichen sclerosus after treatment with a potent topical steroid cream. J Reprod Med 1993;38:25-27.
6. Bracco GL, Carli P, Sonni L, Maestrini G, De Marco A, Taddei GL, et al: Clinical and histologic effects of topical treatments of vulvar lichen sclerosus: a critical evaluation. J Reprod Med 1993;38:37-40.
7. Bornstein J, Heifetz S, Kellner Y, Stolar Z, Abramovici H: Clobetasol dipropionate 0.05% versus testosterone propionate 2% topical application for severe vulvar lichen sclerosus. Am J Obstet Gynecol 1998;178:80-84.
8. Sawada S, Suzuki G, Kawase Y, Takaku F: Novel immunosuppressive agent, FK506. In vitro effects on the cloned T-cell activation. J Immunol 1987;139:1797-1803.
9. Schreiber SL, Crabtree GR: The mechanism of action of cyclosporin A and FK506. Immunol Today 1992;13:136-142.
10. Homey B, Assmann T, Vohr HW, Ulrich P, Lauerma AI, Ruzicka T, et al: Topical FK506 suppresses cytokine and costimulatory molecule expression in epidermal and local draining lymph node cells during primary skin immune responses. J Immunol 1998;160:5331-5340.
11. Regauer S: Immune dysregulation in lichen sclerosus. Eur J Cell Biol 2005;84:273-277.
12. Van Leent EJ, Ebelin ME, Burtin P, Dorobek B, Spuls PI, Bos JD: Low systemic exposure after repeated topical application of pimecrolimus (Elidel®, SD Z ASM 981) in patients with atopic dermatitis. Dermatology 2002;204:63-68.
13. Allen BR, Lakhanpaul M, Morris A, Lateo S, Davies T, Scott G, et al: Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003;88:969-973.
14. Boms S, Gambichler T, Freitag M, Altmeyer P, Kreuter A: Pimecrolimus 1% cream for anogenital lichen sclerosus in childhood. BMC Dermatol 2004;4:14.
15. Goldstein AT, Marinoff SC, Christopher K: Pimecrolimus for the treatment of vulvar lichen sclerosus in a premenarchal girl. J Pediatr Adolesc Gynecol 2004;17:35-37.
16. Goldstein AT, Marinoff SC, Christopher K: Pimecrolimus for the treatment of vulvar lichen sclerosus: a report of 4 cases. J Reprod Med 2004;49:778-780.
17. Bode MK, Mosorin M, Satta J, Risteli L, Juvonen T, Risteli J: Complete processing of type III collagen in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 1999;19:1506-1511.
18. Eriksen HA, Pajala A, Leppilahti J, Risteli J: Increased content of type III collagen at the rupture site of human Achilles tendon. J Orthop Res 2002;20:1352-1357.
19. Gupta A, Chow M: Pimecrolimus: a review. J Eur Acad Dermatol Venereol 2003;17:493-503.
20. Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, et al: The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001;144:507-513.
21. Conroy S: New products for eczema. Arch Dis Child Ed Pract 2004;89:ep23.